• 1.

    Tuttle KR, et al.. Diabetic kidney disease: A report from an ADA Consensus Conference. Diabetes Care 2014; 37:28642883.

  • 2.

    Molitch ME, et al.. Diabetic kidney disease: A clinical update from Kidney Disease: Improving Global Outcomes. Kidney Int 2015; 87:2030.

  • 3.

    Inzucchi SE, et al.. Management of hyperglycemia in type 2 diabetes, 2015: A patient-centered approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015; 38:140149.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 4.

    Davies MJ, et al.. Management of hyperglycemia in type 2 diabetes, 2018: A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2018; 41:26692701.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 5.

    American Diabetes Association. Pharmacologic approaches to glycemic treatment. Section 9. In Standards of Medical Care in Diabetes–2019. Diabetes Care 2019; 42[Suppl 1]:S90S102.

    • Search Google Scholar
    • Export Citation
  • 6.

    Garber AJ, et al.. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm: 2019 executive summary. Endocrine Pract 2019; 25:69101.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 7.

    Das SR, et al.. 2018 ACC Expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes and atherosclerotic cardiovascular disease: A report of the American College of Cardiology task force on expert consensus decision pathways. J Am Coll Cardiol 2018; 72:32003223.

    • Search Google Scholar
    • Export Citation
  • 8.

    Lipscombe L, et al.. Diabetes Canada Clinical Practice Guidelines Expert Committee. 2018 Clinical Practice Guidelines. Pharmacologic glycemic management of type 2 diabetes in adults. Can J Diabetes 2018; 42[Suppl 1]:S88S103.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 9.

    Stone JA, et al.. Diabetes Canada Clinical Practice Guidelines Expert Committee. 2018 Clinical Practice Guidelines. Cardiovascular protection in people with diabetes. Can J Diabetes 2018; 42(Suppl 1):S162S169.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 10.

    McFarlane P, et al.. Diabetes Canada Clinical Practice Guidelines Expert Committee. Chronic kidney disease in diabetes. Can J Diabetes 2018; 42[Suppl 1]:S201S209.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 11.

    Chiang C-E, et al.. 2018 consensus of the Taiwan Society of Cardiology and the Diabetes Association of the Republic of China (Taiwan) on the pharmacological management of patients with type 2 diabetes and cardiovascular disease. J Chinese Med Assoc 2018; 81:189222.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 12.

    LeRoith D, et al.. Treatment of diabetes in older adults: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2019; 104:15201574.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 13.

    Jia W, et al.. on behalf of the Chinese Diabetes Society. Standards of medical care for type 2 diabetes. Diabetes Metab Res Rev 2019; Mar 25:e3158. doi: 10.1002/dmrr.3158.

    • Search Google Scholar
    • Export Citation

Diabetes Guidelines: Where Do the Old and New Agents Fit?

  • 1 Mark Molitch, MD, is the Martha Leland Sherwin Professor of Endocrinology in the division of endocrinology, metabolism, and molecular medicine, department of medicine at Northwestern University Feinberg School of Medicine.
Restricted access
Save